Results 21 to 30 of about 18,898 (135)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis

Journal of Diabetes Research, 2020
Periodontitis is one of the diabetic complications due to its high morbidity and severity in patients with diabetes. The prevention of periodontitis is especially important in diabetic patients because the relationship between diabetes and periodontitis ...
Noritaka Sawada, Kei Adachi, Nobuhisa Nakamura, Megumi Miyabe, Mizuho Ito, Shuichiro Kobayashi, Shin-ichi Miyajima, Yuki Suzuki, Takeshi Kikuchi, Makoto Mizutani, Taku Toriumi, Masaki Honda, Akio Mitani, Tatsuaki Matsubara, Keiko Naruse   +14 more
doaj   +1 more source

Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux

Journal of Pharmacological Sciences, 2021
The incidence of diabetes–associated cognitive dysfunction is increasing. However, few clinical interventions are available to prevent the disorder.
Meng Zhang, Wenhui Yan, Ye Yu, Jie Cheng, Xinyao Yi, Tingli Guo, Na Liu, Jia Shang, Zhuanzhuan Wang, Hao Hu, Lina Chen   +10 more
doaj   +1 more source

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet

Frontiers in Nutrition, 2022
Except for improving glycemic control, liraglutide, one of the glucagon-like peptide-1 receptor agonists, has exerted promising therapeutic effects for dyslipidemia.
Li Zhao, Yue Qiu, Panpan Zhang, Xunan Wu, Zhicong Zhao, Xia Deng, Ling Yang, Dong Wang, Guoyue Yuan   +8 more
doaj   +1 more source

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

PLoS ONE, 2018
BackgroundWe assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.MethodsThe Swedish Institute for Health
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar   +4 more
doaj   +1 more source

418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss

Journal of Clinical and Translational Science, 2022
OBJECTIVES/GOALS: We aimed to determine if GLP-1 receptor agonists exert beneficial effects on surrogate measures of cardiovascular function independently of weight loss.
Mona Mashayekhi, Joshua A. Beckman, Erica M. Garner, Hui Nian, Chang Yu, Sara E. Howard, Bradley Perkins, Jessica K. Devin, John R. Koethe, Jonathan D. Brown, Heidi Silver, James M. Luther, Nancy J. Brown   +12 more
doaj   +1 more source

Liraglutide [PDF]

Reactions Weekly, 2020
  +6 more sources

Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition

Discover Oncology
Background Liraglutide, a glucagon-like peptide-1 receptor agonist commonly used in diabetes management, has shown potential anti-cancer effects across various malignancies.
Xinjian Li, Minghu Fan, Rong Huang, Keqiang Wang, Hunan Huang   +4 more
doaj   +1 more source

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets

Molecular Metabolism, 2023
Objective: Glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1RA) and fibroblast growth factor-21 (FGF21) confer similar metabolic benefits. GLP-1RA induce FGF21, leading us to investigate mechanisms engaged by the GLP-1RA liraglutide to increase ...
Thao D.V. Le, Payam Fathi, Amanda B. Watters, Blair J. Ellis, Gai-Linn K. Besing, Nadejda Bozadjieva-Kramer, Misty B. Perez, Andrew I. Sullivan, Jesse P. Rose, Laurie L. Baggio, Jacqueline Koehler, Jennifer L. Brown, Michelle B. Bales, Kaitlyn G. Nwaba, Jonathan E. Campbell, Daniel J. Drucker, Matthew J. Potthoff, Randy J. Seeley, Julio E. Ayala   +18 more
doaj   +1 more source

A study on the therapeutic effect of liraglutide on chronic renal failure rats by down-regulating TGF-β1 and α-SMA

Linchuang shenzangbing zazhi, 2020
Objective To explore the therapeutic effect of liraglutide on chronic renal failure(CRF)rats by down-regulating transforming growth factor-β1(TGF-β1)and α-smooth muscle actin(α-SMA).Methods Wistar rats were divided into sham group,chronic renal failure ...
CHEN Li, TANG Wen-zhuang, ZHU Mei-juan, CHEN Juan   +3 more
doaj  

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

Clinical Medicine Insights: Endocrinology and Diabetes, 2011
Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage.
Daisuke Yabe, Yutaka Seino
doaj   +1 more source